Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Resectable Pancreatic Adenocarcinoma
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Trial Timeline
Jul 24, 2019 → May 25, 2024
NCT ID
NCT03970252About Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin
Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin is a phase 1 stage product being developed by Bristol Myers Squibb for Borderline Resectable Pancreatic Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03970252. Target conditions include Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03970252 | Phase 1 | Completed |
Competing Products
12 competing products in Borderline Resectable Pancreatic Adenocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 77 |
| olanzapine | Eli Lilly | Pre-clinical | 23 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Durvalumab + Tremelimumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| quetiapine extended-release + Placebo | AstraZeneca | Phase 3 | 77 |
| Quetiapine fumarate + Placebo | AstraZeneca | Phase 2 | 52 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 77 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 51 |
| PD-1/PD-L1 inhibitors + Chemotherapy | BeOne Medicines | Phase 2 | 49 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 36 |
| vafidemstat + Placebo | Oryzon Genomics | Phase 2 | 44 |